Healthcare Cold Chain Third Party Logistics Market Size, Share & Trends Analysis Report By Service (Warehousing & Storage, Packaging Solutions), By Product (Biopharmaceuticals), By Temperature Range, By End Use, By Region, And Segment Forecasts, 2026 - 20

Healthcare Cold Chain Third Party Logistics Market Summary

The global healthcare cold chain third party logistics market size was valued at USD 45.76 billion in 2025 and is projected to reach USD 83.40 billion by 2033, growing at a CAGR of 7.74% from 2026 to 2033. The rising demand for temperature-sensitive pharmaceutical products, stringent global regulations for pharmaceutical storage and distribution and expansion of global pharmaceutical distribution networks.

The growing global demand for vaccines, biologics, cell and gene therapies, and specialty drugs is significantly increasing reliance on cold chain logistics. Biologics, including monoclonal antibodies, gene therapies, and recombinant proteins, require stringent temperature control-typically between 2°C and 8°C, with some requiring ultra-low storage at -70°C or lower-to maintain their efficacy. As more temperature-sensitive products enter the market, pharmaceutical companies require highly specialized storage, packaging, and distribution systems to maintain product efficacy. This rise in biologics and high-value therapies directly drives the need for advanced 3PL providers capable of offering end-to-end temperature control, real-time monitoring, and regulatory compliance. As a result, healthcare companies outsource logistics to experienced cold chain specialists to reduce risk, ensure product quality, and meet global distribution timelines, thereby accelerating the expansion of the healthcare cold chain 3PL market.

In addition, strict guidelines from government bodies such as FDA, EMA, and WHO require exact temperature management, verified transportation protocols, and thorough documentation for the distribution of pharmaceuticals. These regulatory demands create difficulties and expenses for manufacturers attempting to handle logistics on their own. As a result, companies rely on third-party logistics providers that have validated equipment, comply with GDP standards, and utilize advanced monitoring technologies. This transition ensures ongoing compliance with regulations, minimizes the risk of product loss or recalls, and strengthens the integrity of the supply chain.

Furthermore, as pharmaceutical companies expand their presence in emerging markets, the demand for dependable temperature-controlled distribution increases. These areas frequently face challenges such as insufficient cold storage facilities, fragmentated transportation systems, and inconsistent regulatory frameworks. The growth of cell and gene therapies is driving demand for ultra-low and cryogenic cold chain capacity. For instance, Cencora will expand its services in 500,000-sq-ft Texas 3PL facility will greatly expand controlled, refrigerated, frozen, and cryogenic storage capabilities. Thus, pharmaceutical manufacturers are turning to specialized third-party logistics (3PL) providers that possess well-established global networks, validated cold chain processes, and insights into local markets. This trend towards outsourcing helps minimize operational risks, guarantee consistent delivery, and preserve product integrity over long distances and varying climates. The expanding geographic distribution of healthcare products directly enhances the need for sophisticated 3PL cold chain services, thereby driving market growth.

Global Healthcare Cold Chain Third Party Logistics Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global healthcare cold chain third party logistics market based on service, product, temperature range, end use, and region.

• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Transportation
• Air Freight
• Sea Freight
• Overland
• Warehousing & Storage
• Packaging Solutions
• Monitoring & Visibility Solutions
• Inventory Management
• Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceuticals
• Pharmaceuticals
• Medical Device
• Others
• Temperature Range Outlook (Revenue, USD Million, 2021 - 2033)
• Frozen
• Ultra-frozen/Deep-Frozen
• Cryogenic
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• Thailand
• South Korea
• Australia
• Latin America
• Brazil
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Oman
• Qatar

Please note The report will be delivered in 2-3 business days upon order notification. Show more